Larimar Therapeutics, Inc. (Nasdaq: LRMR) has begun dosing adolescents aged 12-17 in its pediatric pharmacokinetic (PK) ...

Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) run-in study will be eligible to screen in ...

Larimar doses adolescents in nomlabofusp paediatric pharmacokinetic run-in study for patients with Friedreich’s ataxia: Bala Cynwyd, Pennsylvania Saturday, January 25, 2025, 15: ...

A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...

Larimar Therapeutics (LRMR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Edward ...

January 30, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of the Company's senior ...

TransCon CNP matches BioMarin's Voxzogo for achondroplasia with plans for regulatory filings in 2025, showing potential for ...

The SAB-142 Phase 1 dose range was between 0.03mg/kg up to 2.5mg/kg, which demonstrated favorable safety profile based on the ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Goniotomy was found to be a safe conjunctival-sparing approach that effectively reduced intraocular pressure over the long ...

SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support that ...